Carbapenem-resistant Enterobacterales species and multidrug-resistant Pseudomonas aeruginosa are global health threats. Cefepime–taniborbactam is an investigational β-lactam and β-lactamase inhibitor ...

Credit: Getty Images. A PDUFA target date of February 22, 2024 has been set for this application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Patients with Enterobacter infections experienced similar outcomes when treated with cefepime and carbapenems, according to a study in Clinical Infectious Diseases. Researchers found none of the ...

Cefepime, a fourth-generation cephalosporin, is a widely used beta-lactam (BL) antibiotic with more than two decades of proven safety and clinical utility against susceptible gram-negative and ...

The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI. Positive results were announced from a phase 3 study evaluating ...

Carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa are a global threat to antimicrobial resistance and may be causative pathogens in cUTI. Cefepime-taniborbactam ...

For bloodstream infections caused by chromosomal AmpC β-lactamase-producing strains, cefepime may be an appropriate carbapenem-sparing treatment option. Cefepime is supported as an alternative to ...

Please provide your email address to receive an email when new articles are posted on . McGovern PC, et al. Abstract 731. Presented at: IDWeek; Oct. 19- 23, 2022. Washington (hybrid meeting). A ...

The frequency of neutropenia in patients receiving long-term cefepime therapy for osteomyelitis compared with that in patients receiving other antimicrobials was studied. A comparative case review was ...

About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this ...

Mortality associated with cefepime (Maxipime) was evaluated in a systematic review and meta-analysis of 57 randomized trials comparing cefepime with another beta-lactam antibiotic; the review was ...